Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 5/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469340 | 0.92 | HPGD (0.50) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL12071961 | 0.92 | HPGD (0.50) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL18275003 | 0.86 | HPGD (0.43) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL22054525 | 0.84 | HPGD (0.53) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL17776135 | 0.83 | NR1H2 (0.47) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL9014148 | 0.83 | KDM4E (0.46) | HPGDRECQLKDM4EMAPTTHRB | |
| SCHEMBL12995623 | 0.82 | USP2 (0.49) | HPGDKDM4EMAPTTHRBKMT2A | |
| SCHEMBL28525339 | 0.82 | MAPT (0.39) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL7051016 | 0.81 | EPHX1 (0.45) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL16186451 | 0.81 | FAAH (0.42) | HPGDRECQLKDM4EMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-11685739-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| CN-112521305-B | Novel high penetration drug for treating Parkinson disease and pharmaceutical composition thereof | 苏州泰飞尔医药有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20220064157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2021-08-19 | — | — | US | disclosed |
| US-11084813-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| EP-0844877-B1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ASTRAZENECA AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-0925286-B1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2003-01-02 | — | — | EP | disclosed |
| US-6093718-A | AN OXIDO-SQUALENE CYCLASE INHIBITOR, ANTICHOLESTEROL AGENT FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND LOWERING CHOLESTEROL LEVELS IN BLOOD PLASMA; TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2000-07-25 | — | — | US | disclosed |
| US-6090813-A | Use of oxido-squalene cyclase inhibitors to lower blood cholesterol | ZENECA LIMITED (GB) | 2000-07-18 | — | — | US | disclosed |
| EP-0925286-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| EP-0844877-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1998006705-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1998-02-19 | — | — | WO | disclosed |
| WO-1997006802-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | HPGD 1974/4885RECQL 27/4885PTPN2 3595/4885 |
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | HPGD 601/4885RECQL 1608/4885PTPN2 4151/4885 |
| US-11084813-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | ABCB1, PARK7, ABCG2 | HPGD 47/4885RECQL 2182/4885PTPN2 3973/4885 |
| US-11685739-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | ABCB1, PARK7, ABCG2 | HPGD 47/4885RECQL 2182/4885PTPN2 3973/4885 |
| US-20220064157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | ABCB1, PARK7, SLC5A7 | HPGD 51/4885RECQL 2042/4885PTPN2 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.